<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222469</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0652</org_study_id>
    <nct_id>NCT00222469</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial of Bevacizumab Plus Gemcitabine™ and Oxaliplatin™ as First Line Therapy in Metastatic or Locally Advanced (Unresectable) Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if giving patients bevacizumab along with the&#xD;
      chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival.&#xD;
&#xD;
      In addition, the study will find out what side effects patients may have by taking&#xD;
      bevacizumab, oxaliplatin, and gemcitabine together.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
        -  A phase II single arm study. All patients receive bevacizumab 10mg/kg and gemcitabine&#xD;
           1000mg/m2 on day 1 followed by oxaliplatin 100mg/m2 on day 2 of a 14 day cycle.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
        -  The purpose of this study is to find out if giving patients bevacizumab, along with the&#xD;
           chemotherapy drugs oxaliplatin and gemcitabine, will improve overall survival. In&#xD;
           addition, the study will find out what side effects patients may have by taking&#xD;
           bevacizumab, oxaliplatin and gemcitabine together.&#xD;
&#xD;
      Enrollment:&#xD;
&#xD;
        -  Approximately 30 patients will be enrolled to the study between the University of&#xD;
           Oklahoma and M.D. Anderson Cancer Center.&#xD;
&#xD;
      Duration:&#xD;
&#xD;
        -  The study will be conducted over approximately 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the overall survival (OS) rate at 1 year in this patient population, treated with the combination therapy of bevacizumab plus gemcitabine and oxaliplatin</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the objective tumor response rate in this patient population. To determine time to progression (TTP) and progression free survival (PFS) in this patient population</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the tolerability and toxicity profile of this regimen in this patient population</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-agent treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>10mg/kg IV on Day 1 Q 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>100mg/m2 on Day 2 and Q 2 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;/= 18 years old&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Patients with metastatic or unresectable locally advanced adenocarcinoma of the&#xD;
             pancreas.&#xD;
&#xD;
          -  Patients who have recurrent disease post pancreaticoduodenectomy no earlier than 6&#xD;
             months after resection. Patients with recurrent disease who had completed adjuvant&#xD;
             therapy in the form of radiation with or without radiosensitizing 5-fluorouracil&#xD;
             (5-FU) 6 months prior to recurrence may be included.&#xD;
&#xD;
          -  Signed informed consent/authorization is obtained prior to conducting any study&#xD;
             specific screening procedures.&#xD;
&#xD;
          -  No prior chemotherapy for advanced pancreatic cancer&#xD;
&#xD;
          -  Patient must have measurable disease&#xD;
&#xD;
          -  Use of effective means of contraception (men and women) in subjects of child-bearing&#xD;
             potential&#xD;
&#xD;
          -  Obstructive jaundice must be relieved before inclusion&#xD;
&#xD;
          -  Adequate hepatic, renal, and bone marrow function: leukocytes &gt;= 3,000/uL, absolute&#xD;
             neutrophil count &gt;= 1,500/uL, platelets &gt;= 100,000/uL, total bilirubin &lt; = 1.5 X&#xD;
             institutional upper limits of normal (ULN), AST (SGOT)/ALT (SGPT) &lt;= 2.5 X&#xD;
             institutional ULN, creatinine &lt;= 1.5 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy for pancreatic cancer.&#xD;
&#xD;
          -  Patients who have recurrent disease within 6 months after pancreaticoduodenectomy or&#xD;
             had received adjuvant therapy within 6 months of disease recurrence.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including:&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
               -  Cardiovascular: New York Heart Association (NYHA) grade II or greater congestive&#xD;
                  heart failure, unstable angina pectoris, cardiac arrhythmias not well controlled&#xD;
                  with medication, myocardial infarction within the previous 6 months, blood&#xD;
                  pressure &gt; 150/100 mmHg&#xD;
&#xD;
               -  Clinically significant peripheral vascular disease&#xD;
&#xD;
               -  History of stroke within previous 6 months&#xD;
&#xD;
               -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to Day 0, anticipation of need for major surgical procedure during the course of&#xD;
             the study.&#xD;
&#xD;
          -  Minor surgical procedures, fine needle aspirations or core biopsies within 7 days&#xD;
             prior to Day 0&#xD;
&#xD;
          -  Urine protein:creatinine ratio &gt; 1.0 at screening&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 28 days prior to Day 0&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Patients with known brain metastases should be excluded from this clinical trial&#xD;
             because of their poor prognosis and because they often develop progressive&#xD;
             neurological dysfunction that would confound the evaluation of neurological and other&#xD;
             adverse events. A computed tomography (CT) scan of the brain is not needed for&#xD;
             eligibility and will be done only if the patient presents with symptoms suggestive of&#xD;
             brain metastases.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents, or have participated&#xD;
             in any investigational drug study within 28 days preceding start of study treatment.&#xD;
&#xD;
          -  The teratogenic potential of this combination is currently unknown. Women who are&#xD;
             pregnant or lactating are excluded.&#xD;
&#xD;
          -  History of any other malignancy in the last 5 years, except patients with a prior&#xD;
             history of in situ cancer or basal or squamous cell skin cancer.&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehrdad Jafari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>July 8, 2008</last_update_submitted>
  <last_update_submitted_qc>July 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mehrdad Jafari, MD</name_title>
    <organization>University of Oklahoma Dept. of Medicine</organization>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>unresectable pancreatic cancer</keyword>
  <keyword>metastatic pancreatic cancer</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>1st line treatment</keyword>
  <keyword>first line treatment</keyword>
  <keyword>locally advanced (unresectable) pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

